Elke Platz

Featured in: Favicon

wiley.com (+1) Favicon

nature.com Favicon

internationaljournalofcardiology.com Favicon

resmedjournal.com

Articles

Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™‐1 and ‐2)

Nov 4, 2024 | onlinelibrary.wiley.com | Sean Wharton |Mikhail Kosiborod |Elke Platz |Martina Brueckmann

What is already known? Antiobesity medications (AOMs) in conjunction with lifestyle changes are recommended for the treatment of obesity, but only a few AOMs are available to combat this highly prevalent and heterogenous disease. Survodutide is a dual glucagon and glucagon-like peptide-1 (GLP-1) receptor agonist under investigation for the treatment of obesity in people with BMI ≥ 30 kg/m2 or ≥27 kg/m2 with at least one obesity-related complication. What do these studies add?

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →